- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04463004
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation
Study Overview
Status
Intervention / Treatment
Detailed Description
This prospective, Phase 2, multi-center, blinded randomized placebo-controlled study is designed to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe Covid-19 pneumonia and clinical and biological features of hyper-inflammation.
The study population includes patients who have severe pneumonia, defined as hospitalization due to Covid-19 with abnormal chest imaging and SpO2 <92% on room air or requirement for supplemental oxygen.
Enrollment: The study will be performed in approximately 4 months total, starting from the first patient enrolled with enrollment expected to complete within 2 months.
Follow-up period: The follow-up period is 60 days for each patient enrolled.
A total of 60 patients will be randomized using a 1:1 allocation ratio: 30 subjects will receive mavrilimumab, and 30 subjects will receive placebo infusion. The investigator, clinical team, and subject will be blinded to treatment assignment.
Participants will be identified by regular review of hospitalized COVID19 patients to evaluate for inclusion and exclusion criteria. Participants will then be approached in the standard manner by study investigator and coordinator/research nurse.
Research interventions will take place in the hospital in accordance with privacy standards.
The study team is informed on all study procedures and requirements with daily meetings and the opportunity to continuously update through secure channels.
In this multicenter consortium, each participating site will have their own IND for patients enrolled at their site. Data collection, data analysis, and randomization scheme will be performed by one site, Cleveland Clinic C5 Research.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent must be obtained before any assessment is performed
- Documented COVID19 pneumonia defined as positive SARS-CoV2 test AND abnormalities/ infiltrates on chest x-ray or computed tomography AND active fever or documented fever within 24-48 hours or ongoing anti-pyretic use to suppress fever
- Hypoxia (Room air SpO2 <92% or requirement for supplemental oxygen)
- Increased serum inflammatory marker (CRP > 5 mg/dL)
- Severity of disease warrants inpatient hospitalization
Exclusion Criteria:
- Onset of COVID-19 symptoms >14 days
- Age < 18 years-old
- Hospitalized >7 days
- Mechanically ventilated
Serious concomitant illness which in the opinion of the investigator precludes the patient from enrolling in the trial, including (but not limited to):
- History of immunodeficiency (congenital or acquired)
- Neutropenia (absolute neutrophil count <1,500/mm3)
- History of solid-organ or bone marrow transplant
- History of current systemic autoimmune or autoinflammatory disease(s) requiring systemic immune-modulating drugs
- History of myeloproliferative disorder or active malignancy receiving cytotoxic chemotherapy
- Pre-existing severe pulmonary disease (i.e. steroid dependent asthma, COPD on home oxygen, or other restrictive/obstructive lung disease requiring home oxygen)
- Pre-existing severe left ventricular systolic dysfunction (i.e. LVEF <35%)
- Known or suspected active tuberculosis (TB), latent TB, or history of incompletely treated TB or at high risk for latent TB (from exposure or prior incarceration)
- History of active or latent viral hepatitis (i.e. Hepatitis B or C)
- Concomitant uncontrolled systemic bacterial or fungal infection
- Concomitant viral infection other than COVID-19 (e.g. Influenza, other respiratory viruses)
- History of chronic liver disease with portal hypertension
- History of end-stage renal disease on chronic renal replacement therapy
- Recent treatment with cell-depleting biological therapies (e.g., anti-CD20) within 12 months, cell-depleting biological therapies (such as anti-tumor necrosis factor [TNF], anakinra, anti-Interleukin [IL]-6 receptor [e.g. tocilizumab], or abatacept) within 8 weeks (or 5 half-lives, whichever is longer), treatment with alkylating agents within 12 weeks, treatment with cyclosporine A, azathioprine, cyclophosphamide, or mycophenolate mofetil (MMF) within 4 weeks
- Recent treatment with intramuscular live (attenuated) vaccine within 4 weeks
- Chronic or recent corticosteroid use > 10 mg/day
- Pregnant. Breast-feeding women are eligible with the decision to continue or discontinue breast-feeding during therapy taking into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother
- Enrolled in another investigational study using immunosuppressive therapy
- Known hypersensitivity to mavrilimumab or any of its excipients
- In the opinion of the investigator, unable to comply with the requirements to participate in the study
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of investigational drug. Such methods include:
- Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
- Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject
- Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention
Treatment infusion
|
Treatment infusion
Other Names:
|
Placebo Comparator: Control
Placebo infusion
|
Placebo infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Subjects Alive and Off of Oxygen at Day 14
Time Frame: 14 days
|
Number of subjects alive and off of oxygen
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Alive and Without Respiratory Failure at 28 Days
Time Frame: 28 days
|
Number of subjects alive and without respiratory failure
|
28 days
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Lung Diseases
- COVID-19
- Inflammation
- Respiratory Insufficiency
- Pneumonia
- Antirheumatic Agents
- Mavrilimumab
Other Study ID Numbers
- HM20019145
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Mavrilimumab
-
MedImmune LLCMedImmune LtdCompletedRheumatoid ArthritisBulgaria, Poland, Russian Federation, South Africa, Spain, Estonia, Hungary, Ukraine, Argentina, Chile, Germany, Serbia, Czech Republic, Colombia
-
MedImmune LLCMedImmune LtdCompletedA Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid ArthritisRheumatoid ArthritisBulgaria, Poland, Russian Federation, Estonia, Hungary, Latvia, Lithuania, Romania, Ukraine, Czechia, Japan
-
MedImmune LLCTerminatedRheumatoid ArthritisBulgaria, Poland, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Hungary, Ukraine, Argentina, Chile, Czechia, Israel, Slovakia, Greece, Germany, Serbia, Colombia, Mexico
-
MedImmune LLCCompletedHealthy VolunteersUnited Kingdom
-
Kiniksa Pharmaceuticals, Ltd.CompletedCOVIDUnited States, Brazil, South Africa, Chile, Peru
-
Ospedale San RaffaeleUnknownCovid-19 | Acute Respiratory Failure | ARDS, Human | Sars-CoV2 | Viral PneumoniaItaly
-
The Cleveland ClinicKiniksa Pharmaceuticals, Ltd.CompletedPneumonia | SARS-CoV 2 | COVID 19United States
-
Kristin HudockKiniksa Pharmaceuticals, Ltd.UnknownPneumonia | SARS-CoV 2 | COVID 19United States
-
MedImmune LLCCompletedRheumatoid ArthritisRussian Federation, Spain, United Kingdom, Argentina, Hungary, Israel, Portugal, Slovakia, Greece, Serbia, Czech Republic, Colombia, France, Mexico
-
Kiniksa Pharmaceuticals, Ltd.CompletedGiant Cell ArteritisUnited States, Belgium, Croatia, Germany, Italy, Poland, Serbia, United Kingdom, Australia, Estonia, Ireland, Netherlands, New Zealand, Slovenia, Spain